Reuters logo
23 天内
BRIEF-Biogen says ‍new data reaffirm clinically meaningful benefit of Spinraza in individuals with spinal muscular atrophy across disease severity​
2017年6月29日 / 中午11点57分 / 23 天内

BRIEF-Biogen says ‍new data reaffirm clinically meaningful benefit of Spinraza in individuals with spinal muscular atrophy across disease severity​

1 分钟阅读

June 29 (Reuters) - Biogen Inc

* Biogen - ‍new data reaffirm clinically meaningful benefit of Spinraza (nusinersen) in individuals with spinal muscular atrophy across disease severity​

* Biogen Inc - ‍Spinraza demonstrated motor function improvements in infants on permanent ventilation

* Biogen Inc - ‍No increase in risk of adverse events in children with Scoliosis​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below